Photocure ASA

Earnings Release • Apr 8, 2019

Photocure: New Data on Cysview® to be presented at the upcoming AUA 2019 Annual Meeting

Photocure: New Data on Cysview® to be presented at the upcoming AUA 2019 Annual Meeting

Oslo, Norway, April 8, 2019: Photocure ASA (PHO:OSE) announced today that

Photocure will be exhibiting Blue Light Cystoscopy (BLCT) with Cysview in Booth

2214, during the American Urological Association Meeting (AUA 2019) in Chicago

May 3rd-6th.

On the booth urologists will have the opportunity to experience BLC with

Cysview, using both the rigid and flexible equipment.

BLC with Cysview will also be presented during plenary and poster sessions at

the AUA annual meeting including:

May 3, 2019 (FRIDAY)

·  10:25 AM to 11:40 AM: Blue Light Cystoscopy for the diagnosis of Bladder

Cancer by Dr. Badrinth Konety from University of Minnesota (Minneapolis, MN),

MCP S105

·  4:45PM - 5:45 PM: Surgical Techniques: Tips & Tricks: Oncology Dr. Lotan,

UTSW, (Dallas Tx) will present BLC with Cysview Flexible during the session

W375e

May 4, 2019 (SATURDAY)

·  3:30 PM - 5:30 PM: Poster presentation: Flexible Blue Light Cystoscopy with

Hexaminolevulinate provides opportunity to finalize Diagnosis and Treatment of

Non-Muscle Invasive Bladder Cancer in the Outpatient Clinic. Results from a

Nordic Registry Study, W181ab

About Bladder Cancer

Bladder cancer is the sixth most commonly diagnosed cancer in the US and is the

fourth most common cancer found in men in the US.(1, 2) It is estimated that

there will be 80,470 new cases of bladder cancer and 17,670 deaths due to

bladder cancer in 2019.(3) Risk factors for bladder cancer include advancing

age, cigarette smoking, occupational exposure to dyes, tar, rubber and solvent,

and chronic bladder irritation and infections.(4) Bladder cancer is one of the

most expensive cancers to manage. It is estimated that upwards of $5.71 billion

will be spent on bladder cancer in the US in the year 2020.(5)

Bladder cancer is classified into two types, non-muscle invasive bladder cancer

(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of

invasion in the bladder wall.(4) NMIBC is in the inner layer of cells.(3) These

cancers are the most common (75%) of all bladder cancer cases and include the

subtypes carcinoma in situ (CIS), Ta and T1 lesions.(5) MIBC is when the cancer

has grown into deeper layers of the bladder wall.(2) These cancers, including

subtypes T2, T3 and T4, are more likely to spread and are harder to treat.(6)

About Hexvix®/Cysview® (hexaminolevulinate HCl)

Hexvix®/Cysview® is a drug that is selectively taken up by tumor cells in the

bladder making them glow bright pink during Blue Light Cystoscopy (BLCTM). BLCT

with Hexvix® /Cysview® improves the detection of tumors and leads to more

complete resection, fewer residual tumors and better management decisions.

Cysview® is the tradename in the US and Canada, Hexvix® is the tradename in all

other markets. Photocure is commercializing Cysview® /Hexvix® directly in the US

and the Nordic region and has strategic partnerships for the commercialization

of Hexvix®/Cysview® in Europe, Canada, Australia and New Zealand. Please refer

to https://bit.ly/2wzqSQQ for further information on our commercial partners.

All trademarks mentioned in this release are protected by law and are registered

trademarks of Photocure ASA.

For more information, please contact:

Dan Schneider

President and CEO

Photocure ASA

Tel: + 1-609 759-6515

Email: ds@photocure.com

Erik Dahl

CFO

Photocure ASA

Tel: +4745055000

Email: ed@photocure.com

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to

improve the lives of bladder cancer patients. Our unique technology, which makes

cancer cells glow bright pink, has led to better health outcomes for patients

worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo

Stock Exchange (OSE: PHO). For more information, please visit us at

www.photocure.com, www.hexvix.com or www.cysview.com

----------------------------------------------------------------------

1 National Cancer Institute. SEER Stat Facts: Bladder Cancer 2017.

https://seer.cancer.gov/statfacts/html/urinb.html. Accessed on January 25, 2019.

(http://#_ftnref2)2 American Cancer Society's (ACS) publication. Cancer Facts

and Figures 2017: Special Section - Rare Cancers in Adults, and the ACS

website. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and

-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures

-2017.pdf.  Accessed on March 25, 2019.

3 American Cancer Society. Key Statistics for Bladder Cancer 2019.

https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html. Accessed

on March 25, 2019.

(http://#_ftnref4)4 American Cancer Society. Bladder Cancer.

http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer

-additional. Accessed on March 25, 2019.

(http://#_ftnref5)5 Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML.

Projections of the cost of cancer care in the United States: 2010-2020. J Natl

Cancer Inst. 2011;103(2):117-28.

(http://#_ftnref6)6 Pulver D, Schoenberg M, Pulver F. Bladder Cancer: A Patient

-Friendly Guide to Understanding Your Diagnosis and Treatment Options. Patient

-Friendly Publishing; 2017.